Hypertensive hypertrophic cardiomyopathy may be a distinctive cardiac condition resulting from hypertension. Alternatively, this disease may represent the coincidence of a common disease, hypertension, with a relatively rare cardiomyopathy. A consecutive series of patients with hypertrophic cardiomyopathy and hypertension were studied and compared with age-and gender-matched patients with cardiomyopathy alone.
In 1957, when Brock (1) described in an elderly patient severe hypertrophy of the left ventricle that produced a left ventricular outflow tract obstruction simulating severe symptomatic aortic stenosis, he concluded that this disease was secondary to severe hypertension. In 1959 he (2) suggested that hypertension might not be the "chief factor" when he reported that in a new series of six patients with myocardial hypertrophy, only two had a history of hypertension, In 1958, Teare (3) described severe left ventricular hypertrophy that simulated a tumor in the heart; the patients were young, and none had hypertension. Since that time, numerous patients with hypertrophic cardiomyopathy have been studied. The heart in this condition is now characterized by a hypertrophied, nondilated left ventricle with decreased compliance and impaired diastolic relaxation. Fea-calcification (31 versus 31%), septal thickness >20 mm (56 versus 46%) and outflow tract gradient >20 mm (59 versus 67%). A posterior wall thickness >13 mm was more frequent in the hypertensive group (54%) compared with the nonhypertensive group (31%) (p = 0.02).
The findings show that hypertrophic cardiomyopathy with associated hypertension is a disease of the elderly. But, with the exception of thicker walls, the clinical and echocardiographic features of the patients with hypertension were indistinguishable from those of the age-matched and, hence, elderly group of patients with cardiomyopathy without hypertension. These findings suggest that hypertension may make hypertrophy worse, but that it is not the primary cause of the cardiomyopathy. Thus, the condition might be better termed "hypertrophic cardiomyopathy with hypertension." tures of this disease may also (but do not necessarily) include asymmetric hypertrophy, a histologic pattern of myocardial fiber disarray, a left ventricular outflow tract gradient and systolic anterior motion of the mitral valve.
Thus, the definition of this condition has become simply nondilated hypertrophy with abnormalities of systolic and diastolic function of no known cause. Regardless of its origin, however, hypertrophy can be associated with these structural and functional abnormalities. Consequently, other causes of hypertrophy-e.g., aortic stenosis, hypertension or (rarely) myocardial infiltrative diseases such as amyloid (4) or glycogen storage disease @)-are excluded in making this diagnosis.
One potentially coexisting condition continues to be problematic in assessing whether hypertrophic cardiomyopathy is "idiopathic" or "secondary;" namely, mild to moderate systemic hypertension. Some investigators (6) (7) (8) include patients with hypertension in studies of hypertrophic cardiomyopathy, whereas others (9-11) do so only sometimes. What is not clear from these diverse approaches is whether hypertrophic cardiomyopathy with hypertension is a distinct pathophysiologic subset of hypertrophic cardiomy-opathy in which blood pressure elevation is likely causal or whether systemic hypertension is an associated, but at most aggravating, condition superimposed on an underlying cardiomyopathy.
To address this issue, we studied 39 consecutive patients with the diagnosis of hypertrophic cardiomyopathy who also had systemic hypertension of mild to moderate severity and compared them with an age-and gender-matched group of patients with hypertrophic cardiomyopathy who were normotensive and had no history of hypertension. The findings show that hypertrophic cardiomyopathy is similar in all respects in patients with and without systemic hypertension, and suggest that hypertension may be a cofactor but is likely not a cause of their cardiac disease.
Methods
Patients studied. We reviewed the records of the echocardiographic laboratory at The Cleveland Clinic Foundation between January 1986 and December 1987 for the diagnosis of hypertrophic cardiomyopathy. The only criteria for exclusion were a poor quality echocardiogram and the presence of primary valvular disease or end-stage renal disease. All patients had an echocardiogram because of some clinical suspicion of cardiac disease.
The diagnosis was based on accepted criteria, combining echocardiographic, Doppler and cardiac catheterization data. In addition to left ventricular hypertrophy (septum 2 15 mm with a normal to small-sized cavity), a combination of the following variables was present: systolic anterior motion of mitral valve at rest or with provocation; presence of a gradient in the left ventricular outflow tract by Doppler ultrasound or cardiac catheterization, at rest or with provocation; and asymmetry of the interventricular septum. The clinical charts and echocardiographic studies were reviewed separately and at different times for all patients.
After reviewing the clinical data, we identified those patients (Group 1) who had hypertrophic cardiomyopathy and arterial hypertension. We then selected from our computer data bank a second comparison group (Group 2) from the remaining 74 patients with hypertrophic cardiomyopathy alone. Thirty-nine of the 74 patients were chosen at random to provide age-and gender-match with patients in Group I.
Clinical data. Data were collected from clinical records. Functional class was based on the New York Heart Association classification (I to IV). Hypertension was defined as blood pressure >140/90 mm Hg in the young and >160/95 mm Hg in the elderly (>65 years), as recommended by the Framingham study (12) . The electrocardiograms (ECG) were reviewed for the following: 1) cardiac rhythm; 2) left ventricular hypertrophy, as defined by S wave in lead V, + R wave in lead V, or S wave in lead V, + R wave in lead V, ~-35 mm, or R wave in lead aVL 2 11 mm or combinations; 3) presence of a Q wave in the anteroseptal or lateral precordial leads; and 4) intraventricular conduction abnormalities.
Echocardiographic data. Echocardiographic studies were performed with use of either a Hewlett-Packard instrument with a 2.5/l .9 MHz transducer, an Aloka 880 instrument with a 3.512.0 MHz transducer or an Irex Meridian instrument with a 3.512.0 MHz transducer. All images were recorded on 0.5 in. (1.27 cm) VHS video tape recorders. Tapes were reviewed on a Panasonic editing controller system with a Panasonic AG-6500 video recorder. Each echocardiographic study was reviewed by three investigators without knowledge of patient age or clinical data. Only those echocardiograms that were technically inadequate for detailed analysis were discarded from the study. The following variables were identified as features for analysis during formal prospective evaluation of the echocardiograms: 1) Symmetry or asymmetry was determined by using both
M-made und two-dimensional echocardiography.
Measurements of wall thickness that led to the final determination were obtained from the M-mode recording. Wall thickness measurements were made according to the American Society of Echocardiography (ASE) recommendations for measurements of the septum and posterior wall of the left ventricle (13) .
2
) Systolic anterior motion of the mitral valve was recognized with M-mode and two-dimensional echocardiography
when a displacement of the anterior or posterior leaflets, or both, toward the septum in systole was observed, with or without amyl nitrite provocation.
3) Mitral annular calcification was looked for and described as an increased echo density of the anulus in the parasternal long-axis, short-axis and four-chamber views. in the apical four-chamber view, and described when the right ventricular free wall appeared increased in thickness and there was muscular obliteration of the moderator band and apex leading to loss of the normal crescent shape of the cavity. To help substantiate right ventricular free wall prominence, the parasternal short-and long-axis views were also used whenever they were well visualized.
Statistical analysis. A Student's t test was used to compare mean values between groups. Associations for contingency table data were tested using the chi-square statistic when appropriate. For tables with small expected cell frequencies. exact tests (Fisher's exact or an exact chi-square) were used; p values so.01 were considered to be statistically significant.
Results
Clinical findings (Table 1) . One hundred thirteen patients were evaluated at the Cleveland Clinic between 1986 and 1987 and diagnosed as having hypertrophic cardiomyopathy. Of these, 39 patients with both hypertrophic cardiomyopathy and systemic hypertension (Group 1) were identified. They ranged in age from 31 to 84 years (mean + SD 60 ? 13); 82% of them were >50 years old. The remaining 74 patients with the diagnosis of hypertrophic cardiomyopathy without hypertension were significantly younger (49.7 + 18 years; p < 0.001). Eighteen (46%) of the 39 Group 1 patients were women. The duration of hypertension ranged from 1 to 40 years (mean 11 + 9) in the 23 patients in whom it was known. These 23 patients had an average blood pressure of 188.4 -+ 27 mm Hg systolic and 99 ? 21 mm Hg diastolic. All patients had their blood pressure controlled with medications.
Comparison group. By comparison, Group 2 consisted of 39 of the 74 patients with hypertrophic cardiomyopathy without hypertension, matched for age and gender with Group 1 patients. Cardiac symptoms, murmurs, functional class and ECG abnormalities were virtually identical in the two groups.
Echocardiographic findings ( Table 2 ). All 39 patients with hypertrophic cardiomyopathy and hypertension (Group 1) had septal hypertrophy 215 mm. Septal thickness was 15 to 20 mm in 17 patients (44%) and >20 mm in 22 (55%); the mean thickness was 20 + 3.7 mm. The posterior free wall of the left ventricle was >13 mm in 21 patients (54%) (mean 14 ? 2.5). The septum to free-wall ratio was > 1.3 in 24 patients (62%). Systolic anterior motion of the mitral valve was present in 17 patients (44%) at rest and in 13 (33%) after provocation with amyl nitrite.
Fractional shortening was >30% in 38 patients (97%) (mean 46 ? 8.6%). End-diastolic diameter was ~55 mm in 33 patients (85%) (mean 43 2 6.9 mm); end-systolic diameter was ~35 mm in 37 patients (95%) (mean 24 + 6.4). The left atria1 dimension was >40 mm in 28 patients (72%) (mean 43 + 6.9) and the aortic root dimension was ~40 mm in 38 patients (97%) (mean 35 ? 4.2). Mitral calcification was present in 12 patients (31%), of whom 1 was 53 years old and the remaining 11 were >60 years old. The left ventricular outflow gradient was >20 mm Hg in 23 patients (59%) (mean 80 r 34).
In the left ventricle, reversal of the normal septal curvature was seen in seven patients (18%); in six of them, the right ventricular wall was also prominent, suggesting right ventricular hypertrophy. A normal contoured ovoid ventricle was present in the remaining 32 patients (82%), and 18 (46%) of them also had a proximal septal bulge. There was no correlation between left ventricular shape and levels of blood pressure in Group 1.
Echocardiographic findings in Group 2 were similar to those in Group 1, with one exception. The posterior wall thickness was >13 mm in 12 patients (31%) in Group 2 and the mean value in Group 2 of 13 t 2.6 mm was significantly less than that of Group 1 patients with hypertension. In Group 2, all patients had a septal wall thickness >15 mm (mean 20 ? 4.7); and 18 (46%) had a septal wall thickness >20 mm.
There were no significant differences between the two groups in systolic anterior motion of the mitral valve at rest and after provocation, fractional shortening, end-diastolic diameter, end-systolic diameter, left atria1 dimension and aortic root dimension. The left ventricular outflow gradient was >20 mm Hg in 26 patients (67%) (mean 85 +-45). Reversed septal curvature was observed in 12 patients (31%), and 11 of them also had right ventricular wall prominence. An ovoid left ventricle was present in 27 patients (69%) of whom 13 (33%) had a proximal septal bulge. Mitral calcification was present in 12 patients (31%), all of them *p = 0.02; tp = 0.03. AR = aortic root dimension; EDD = end-diastolic diameter; ESD = end-systolic diameter; FS = fractional shortening; LA = left atrial dimension; Mitral talc = annular calcification; Post wall = posterior wall; SAM = systolic anterior motion of the mitral valve; Sept = septum. >60 years old. None of these findings differed from those found in Group 1 patients with hypertension.
Discussion
Role of hypertension in hypertrophic cardiomyopathy. Hypertension of mild to moderate degree sometimes occurs in patients with hypertrophic cardiomyopathy, but predominantly among the elderly. Our 39 hypertensive patients in Group 1 had a mean age of 60 years, and were significantly older than the 74 patients with hypertrophic cardiomyopathy without hypertension studied during the same time period. Comparison of Group 1 patients with the 39 age-and gender-matched patients with hypertrophic cardiomyopathy without hypertension, however, revealed no differences in symptoms, functional class, ECG changes, left ventricular outflow tract obstruction or most echocardiographic findings, including asymmetric hypertrophy. One notable exception was that those with hypertension were apt to have a thicker posterior left ventricular wall. These findings suggest that the cardiac disease of patients who present with hypertrophic cardiomyopathy with blood pressure elevation is indistinguishable from idiopathic hypertrophic cardiomyopathy and not a distinct condition necessarily related to hypertension. Of particular importance, the patients with hypertension had the same diverse spectrum of disease forms (including symmetry and asymmetry, obstruction and nonobstruction and systolic anterior motion and normal mitral motion) as did those without hypertension.
Top01 et al. (14) recently described severe concentric hypertrophy and heart failure in 21 patients 259 years of age with mild to moderate hypertension. Although they labeled the syndrome "hypertensive hypertrophic cardiomyopathy" to distinguish it from the "classic" hypertrophic cardiomyopathy associated with asymmetric hypertrophy, the hypertrophy was more severe than that ordinarily seen with hypertension, and they viewed the disease as part of the spectrum of hypertrophic cardiomyopathy. Our studies further suggest that excluding these patients by attributing their disease to high blood pressure may obsure the fact that we do not fully understand the cause of this disease.
A relevant issue, raised by Tarazi and Levy (IS), is that the severity of hypertrophy often cannot be related to the severity or duration of hypertension. They suggested that some patients may have a predisposed myocardial sensitivity to the development of hypertrophy in the setting of hypertension. Other investigators (16) have shown clearly that only a minority of patients with chronic mild to moderate hypertension develop clinically detectable left ventricular hypertrophy. Disease prevalence data also indicate that systemic hypertension, a common disorder, does not predictably lead to cardiomyopathy, a relatively rare condition. Hypertension (defined as a blood pressure > 140190 mm Hg) is present in approximately two-thirds of patients 265 years old and in one-third of the general population (17) .
H!:pertension may, however, be a cofactor, if not necessarily the cause of cardiomyopathic remodeling. In a heart with hypertrophic cardiomyopathy it might be expected to aggravate the condition by leading to an additional increase in myocardial mass. This is suggested by our study, in which hypertensive patients had more free wall hypertrophy than did normotensive patients. In the patients with hypertension, however, there was no evidence that their clinical condition was worsened by their elevated blood pressure.
Diagnostic implications. There are inconsistencies in how hypertension is regarded in the setting of hypertrophic cardiomyopathy. A history of hypertension has been used as an exclusion criterion when making the diagnosis of idiopathic hypertrophic cardiomyopathy (9,lO) but there are many exceptions. In 1966, in one of the earliest reports of hypertrophic cardiomyopathy in the elderly, Sanders et al. (18) described this condition in two sisters. one with a blood pressure of 190/100 mm Hg. In an autopsy study (7) of idiopathic hypertrophic cardiomyopathy in which all patients had asymmetric hypertrophy and myocardial fiber disarray in the septum, one-third of them had a prior history of hypertension. In a recent study (8) of the frequency and significance of mitral annular calcification in hypertrophic cardiomyopathy, 10 of 16 patients 265 years old were hypertensive. Some investigators (11) exclude patients with systemic hypertension in their studies, unless they believe that the degree of hypertrophy is greater than would be expected in patients with hypertension alone. The latter is a highly subjective determination. Thus, although some exclude patients from the diagnosis of hypertrophic cardiomyopathy if there is a history of hypertension, exclusion criteria are quite variable and create inconsistencies in our clinical diagnosis and approach to patients with either hypertension or cardiomyopathy.
Conclusions. Hypertrophic cardiomyopathy with hypertension appears to be part of the diverse spectrum of idiopathic hypertrophic cardiomyopathy. Although hypertension with hypertrophic cardiomyopathy is more apt to occur in the elderly, the differences are minimal between hypertrophic cardiomyopathy in patients with and those without hypertension when matched for age. Thus, in both young and old patients, and in those with or without hypertension, hypertrophic cardiomyopathy must be explained by factors other than blood pressure. To label this condition "secondary" when hypertension is present at best creates the satisfaction of defining etiology, but at worst obscures the real uncertainties as to the cause and relation to other forms of the disease. Thus, the condition (or conditions) might be better termed hypertrophic cardiomyopathy with hypertension, rather than hypertensive hypertrophic cardiomyopathy.
